FOLR1 and cancer: Several studies have shifted focus to the FRα isoform as a molecular target in many cancers, including studies on FRα antibodies, high-affinity antifolates, folate-based imaging agents, folate-conjugated drugs, and folate-conjugated nanoparticle delivery systems [22,25,26,27].